HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

[1]  T. Zima,et al.  Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  N. Buza,et al.  The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. , 2022, Pathology.

[3]  J. Rahnenführer,et al.  Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. , 2022, European journal of cancer.

[4]  M. Fassan,et al.  HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment , 2022, npj Breast Cancer.

[5]  Kevin M. Waters,et al.  Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers , 2022, Diseases.

[6]  E. de Azambuja,et al.  The Exciting New Field of HER2-Low Breast Cancer Treatment , 2021, Cancers.

[7]  T. Chano,et al.  Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review , 2019, Healthcare.

[8]  O. Fadare,et al.  Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary. , 2019, Surgical pathology clinics.

[9]  H. Kajiyama,et al.  Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma , 2019, Journal of gynecologic oncology.

[10]  S. Durinck,et al.  Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. , 2018, Cancer cell.

[11]  H. Hollema,et al.  HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in‐situ hybridisation , 2018, Histopathology.

[12]  J. Yasuda,et al.  Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing , 2018, Genes, chromosomes & cancer.

[13]  B. Taylor,et al.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.

[14]  H. Watari,et al.  Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma , 2017, British Journal of Cancer.

[15]  T. Hachisuga,et al.  Clinical statistics of gynecologic cancers in Japan , 2017, Journal of gynecologic oncology.

[16]  Fei Liu,et al.  Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy , 2017, Journal of Ovarian Research.

[17]  M. Ohira,et al.  Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. , 2017, Gynecologic oncology.

[18]  H. Boot,et al.  HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison , 2015, Journal of Cancer Research and Clinical Oncology.

[19]  J. Brenton,et al.  Molecular pathogenesis of ovarian clear cell carcinoma. , 2015, Future oncology.

[20]  G. Coukos,et al.  Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels , 2012, PloS one.

[21]  Hiroshi Kobayashi,et al.  Molecular genetics and epidemiology of epithelial ovarian cancer (Review). , 2011, Oncology reports.

[22]  M. Hoopmann,et al.  Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. , 2010, European journal of cancer care.

[23]  J. Kigawa,et al.  Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma , 2008, Cancer science.

[24]  D. Huntsman,et al.  Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  Yun Wu,et al.  Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. , 2004, Gynecologic oncology.

[26]  Tadao Tanaka,et al.  Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. , 2004, Gynecologic oncology.

[27]  B. No̸rgaard-Pedersen,et al.  Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma , 2003, Cancer.

[28]  S. Hirata,et al.  HER‐2/neu expression in ovarian clear cell carcinomas , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[29]  M. Sakai,et al.  HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab , 2002, Japanese journal of cancer research : Gann.

[30]  J. Ross,et al.  HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. , 1999, American journal of clinical pathology.